deucravacitinib
bms
['poetyk pso,(-poetyk pso1),(-poetyk pso2)', 'psoriasis', 'deucrava', 'deucra']
congress #eadvcongress | mark lebwohl shared long-term efficacy results from the phase 3 poetyk pso study. the trial enrolled pts with moderate-to-severe plaque #psoriasis.
as observed, % of patients on deucravacitinib achieving pasi 75 at week 112 was 84.4% 
The Psoriasis and Psoriatic Arthritis Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education.